Search

Displaying results 3281 - 3290 of 5925 in total
  1. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  2. Drug

    Benzthiazide

    go.drugbank.com/drugs/DB00562
    Approved

    Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity.

  3. Drug

    Methylcellulose

    go.drugbank.com/drugs/DB11228
    ApprovedInvestigational

    The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum of 3, however more typical values

  4. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA.

  5. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia due

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Zapomeran

    go.drugbank.com/drugs/DB21761
    Approved

    [L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell.

  7. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]

    Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitors
  8. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no...

  9. Drug

    Bimatoprost grenod

    go.drugbank.com/drugs/DB21634
    Experimental

    Bimatoprost grenod has a monoisotopic molecular weight of 574.33 Da.

  10. Drug

    Phenarsone sulfoxylate

    go.drugbank.com/drugs/DB21104
    Experimental

    Phenarsone sulfoxylate has a monoisotopic molecular weight of 310.94 Da.